drugset / Trial / NCT06969001

Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops

NCT06969001

Phase 1 Completed 48 enrolled SCAI Therapeutics
RandomizedSequentialDouble-blindOther

Summary

To assess the single-dose and multiple-dose pharmacokinetics (PK), safety and tolerability of SCAI-005 eyedrops(axitinib) in healthy volunteers

Timeline

Start
2025-05-29
Primary completion
2025-09-04
Completion
2025-09-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule 0.014 mg Other
Subject Axitinib Small molecule 0.028 mg Other
Subject Axitinib Small molecule 0.056 mg Other